



Claris

April 11, 2016

The Department of Corporate Services
BSE Limited
25th Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

Dear Sir,

Sub. : Statement of Investor Complaints for the quarter ended on March 31, 2016
Scrip code : 533288

Please find enclosed Statement of Investor Complaints for the quarter ended on March 31, 2016, pursuant to Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

Request you to take the above information on your record.

Thanking You.

Yours faithfully,

For Claris Lifesciences Limited

Kirit Kanjaria

Sr. VP- Company Secretary & Compliance Officer

Encl: a/a

Claris Lifesciences Limited

Claris Corporate Headquarters, Nr. Parimal Rly. Crossing,
Ellisbridge, Ahmedabad 380 006, India.
Tel: +91-79-26563331, 66309339 Fax: +91-79-26408053
www.clarislifesciences.com

(Corporate Identity Number: L85110GJ1994PLC022543)



Claris


Statement of Investor Complaints pursuant to Regulation 13(3) of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015

Name of the Company : Claris Lifesciences Limited
Quarter ending : March 31, 2016

Particulars	No of Grievances
Number of investor complaints pending at the beginning of the Quarter	Nil
Number of investor complaints received during the Quarter	01
Number of investor complaints disposed of during the Quarter	01
Number of investor complaints remaining unresolved at the end of the Quarter	Nil

For Claris Lifesciences Limited

Date: April 11, 2016
Place: Ahmedabad


Kirit Kanjaria
Sr. VP- Company Secretary & Compliance Officer

Claris Lifesciences Limited

Claris Corporate Headquarters, Nr. Parimal Rly. Crossing,
Ellisbridge, Ahmedabad 380 006, India.
Tel: +91-79-26563331, 66309339 Fax: +91-79-26408053
www.clarislifesciences.com

(Corporate Identity Number: L85110GJ1994PLC022543)